Partnering For Success: Microbiological Testing In Contract Laboratories

By Zachary Beck, Group Leader; Michael Hostetter, Senior Scientist I, Eurofins BioPharma Product Testing

Outsourcing microbiological testing is rarely where most biopharmaceutical teams focus their quality strategy, but it probably should be. The decisions you make at the partnership level, before a single sample is tested, have a direct effect on release timelines, regulatory outcomes, and your ability to absorb the unexpected.

Authored by Zachary Beck and Michael Hostetter of Eurofins BioPharma Product Testing, this piece makes the case that successful outsourcing starts with communication, not methodology. Yes, selecting the right sterility, endotoxin, or particulate matter method matters. But without early alignment on product characteristics, matrix interferences, and submission strategy, even a technically sound method can create delays.

Regulatory bodies including the FDA, EMA, and PMDA now expect well-documented method suitability and scientifically justified decisions, not just validated procedures. If you're targeting multiple markets, that complexity compounds: bridging data, historical trend comparisons, and recombinant endotoxin assay transitions all require coordinated planning that a transactional lab relationship simply won't support.

The operational resilience piece is equally underappreciated. Redundant isolators, backup reagent suppliers, in-house media preparation, and multiple trained analysts aren't nice-to-haves. They're what keeps your release schedule intact when something goes wrong.

Download now to evaluate your current outsourcing approach against these criteria before your next program hits a critical milestone.